Assessing Mathematical Models of Influenza Infections Using Features of the Immune Response

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Dobrovolny, Hana M ^a,d   Reddy, Micaela B ^b   Kamal, Mohamed A ^b   Rayner, Craig R ^c   Beauchemin, Catherine A A ^d  

^a TEXAS CHRISTIAN UNIVERSITY   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

^c MONASH UNIVERSITY   (Australia)

^d RYERSON UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; SIALIDASE INHIBITOR; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL THERAPY; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE RESPONSE; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; INFLUENZA; INFLUENZA A (H1N1); MATHEMATICAL MODEL; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; QUALITATIVE ANALYSIS; VIRUS IMMUNITY; VIRUS SHEDDING;

ANIMALS; ANTIBODIES, VIRAL; HUMANS; IMMUNOCOMPROMISED HOST; INFLUENZA A VIRUS; INFLUENZA, HUMAN; INTERFERONS; MODELS, IMMUNOLOGICAL; ORTHOMYXOVIRIDAE INFECTIONS; T-LYMPHOCYTES, CYTOTOXIC; VIRUS SHEDDING;

EID: 84874514993     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057088     Document Type: Article

References (118)

1. CDC (2008) Inuenza activity-united states and worldwide, 2007-08 season. Morb Mortal Wkly Rep 57: 692-697.
2. Bocharov GA, Romanyukha AA, (1994) Mathematical model of antiviral immune response III. Inuenza A virus infection. J Theor Biol 167: 323-360.
3. Beauchemin C, Samuel J, Tuszynski J, (2005) A simple cellular automaton model for inuenza A viral infections. J Theor Biol 232: 223-234.
4. Baccam P, Beauchemin C, Macken CA, Hayden FG, Perelson AS, (2006) Kinetics of inuenza A virus infection in humans. J Virol 80: 7590-7599.
5. Beauchemin CA, McSharry JJ, Drusano GL, Nguyen JT, Went GT, et al. (2008) Modeling aman-tadine treatment of inuenza A virus in vitro. J Theor Biol 254: 439-451.
6. Handel A, Jr IML, Antia R, (2009) Antiviral resistance and the control of pandemic inuenza: The roles of stochasticity, evolution and model details. J Theor Biol 256: 117-125.
7. Handel A, Longini IM, Antia R, (2007) Neuraminidase inhibitor resistance in inuenza: Assessing the danger of its generation and spread. PLoS Comput Biol 3: 2456-2464.
8. Dobrovolny HM, Gieschke R, Davies BE, Jumbe NL, Beauchemin CAA, (2011) Neuraminidase inhibitors for treatment of human and avian strain inuenza: A comparative study. J Theor Biol 269: 234-244.
9. Agrati C, Gioia C, Lalle E, Cimini E, Castilletti C, et al. (2010) Association of profoundly impaired immune competence in H1N1v-infected patients with a severe or fatal clinical course. J Infect Dis 202: 681-689.
10. Barber WH, Parker A Small J, (1978) Local and systemic immunity to inuenza infections in ferrets. Infect Immun 21: 221-228.
11. Iwasaki T, Nozima T, (1977) The roles of interferon and neutralizing antibodies and thymus dependence of interferon and antibody production. J Immunol 118: 256-263.
12. Hsieh SM, Chang SC, (2006) Insufficient perforin expression in CD8+ T cells in response to hemagglutinin from avian inuenza (H5N1) virus. J Immunol 176: 4530-4533.
13. Seo SH, Hoffmann E, Webster RG, (2002) Lethal H5N1 inuenza viruses escape host anti-viral cytokine responses. Nature Med 8: 950-954.
14. AzambujaM (2010) A parsimonious hypothesis to the cause of inuenza lethality and its variations in 19181919 and 2009. Med Hypotheses 74: 681-684.
15. Doherty PC, Turner SJ, Webby RG, Thomas PG, (2006) Inuenza and the challenge for immunology. Nature Immunol 7: 449-454.
16. Frolov AF, Skripchenko GS, Shcherbinskaya AM, Vlasova AG, Rybakova TM, (1984) Peculiarities of inuenza infection caused by highly and poorly immunogenic strains of inuenza virus. J Hyg Epidemiol Microbiol Immunol 29: 303-309.
17. Gentile DA, Doyle WJ, Fireman P, Skoner DP, (2001) Effect of experimental inuenza A infection on systemic immune and inammatory parameters in allergic and nonallergic adult subjects. Ann Allergy Asthma Immunol 87: 496-500.
18. Hayden FG, Fritz RS, Lobo MC, AlvordWG, Strober W, et al. (1998) Local and systemic cytokine responses during experimental human inuenza A virus infection. J Clin Invest 101: 643-649.
19. Kaiser L, Fritz RS, Straus SE, Gubareva L, Hayden FG, (2001) Symptom pathogenesis during acute inuenza: interleukin-6 and other cytokine responses. J Med Virol 64: 262-268.
20. Fritz RS, Hayden FG, Calfee DP, Cass LMR, Peng AW, et al. (1999) Nasal cytokine and chemokine response in experimental inuenza A virus infection: Results of a placebo-controlled trial of intravenous zanamivir treatment. J Infect Dis 180: 586-593.
21. Svitek N, Rudd PA, Obojes K, Pillet S, von Messling V, (2008) Severe seasonal inuenza in ferrets correlates with reduced interferon and increased IL-6 induction. Virol 376: 53-59.
22. Lee HY, Topham DJ, Park SY, Hollenbaugh J, Treanor J, et al. (2009) Simulation and prediction of the adaptive immune response to inuenza A virus infection. J Virol 83: 7151-7165.
23. Miao H, Hollenbaugh JA, Zand MS, Holden-Wiltse J, Mosmann TR, et al. (2010) Quantifying the early immune response and adaptive immune response kinetics in mice infected with inuenza A virus. J Virol 84: 6687-6698.
24. McLaren C, Butchko GM, (1978) Regional T- and B-cell responses in inuenza-infected ferrets. Infect Immun 22: 189-194.
25. Hoshino A, Takenaka H, Mizukoshi O, Imanishi J, Kishida T, et al. (1983) Effect of anti-interferon serum of inuenza virus infection in mice. Antiviral Res 3: 59-65.
26. Vahlenkamp TW, Harder TC, (2006) Inuenza virus infections in mammals. Berl Munch Tierarztl Wochenschr 119: 123-131.
27. Renegar K, (1992) Inuenza virus infections and immunity: a review of human and animal models. Lab Anim Sci 42: 222-232.
28. Haley PJ, (2003) Species differences in the structure and function of the immune system. Toxicology 188: 49-71.
29. Mestas J, Hughes CCW, (2004) Of mice and not men: Differences between mouse and human immunology. J Immunol 172: 2731-2738.
30. Staeheli P, Haller O, (1987) Interferon-induced Mx protein: a mediator of cellular resistance to inuenza virus. Interferon 8: 1-23.
31. Hancioglu B, Swigon D, Clermont G, (2007) A dynamical model of human immune response to inuenza A virus infection. J Theor Biol 246: 70-86.
32. Saenz RA, Quinlivan M, Elton D, MacRae S, Blunden AS, et al. (2010) Dynamics of inuenza virus infection and pathology. J Virol 84: 3974-3983.
33. Handel A, Longini IM, Antia R, (2010) Towards a quantitative understanding of the within-host dynamics of inuenza A infections. J R Soc Interface 7: 35-47.
34. Tridane A, Kuang Y, (2010) Modeling the interaction of cytotoxic T lymphocytes and inuenza virus infected epithelial cells. Math Biosci Eng 7: 176-189.
35. Nowak M, Bonhoeffer S, Hill A, Boehme R, Thomas H, et al. (1996) Viral dynamics in hepatitis B viral infection. Proc Natl Acad Sci USA 93: 4398-4402.
36. Chang DB, Young CS, (2007) Simple scaling laws for inuenza A rise time, duration, and severity. J Theor Biol 246: 621-635.
37. Pawelek KA, Huynh GT, Quinlivan M, Cullinane A, Rong L, et al. (2012) Modeling within-host dynamics of inuenza virus infection including immune responses. PLoS Comput Biol 8: e1002588.
38. Miao H, Xia X, Perelson AS, Wu H, (2011) On identfablity of nonlinear ODE models and applications in viral dynamics. SIAM Review 53: 3-39.
39. Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, et al. (1999) Use of the oral neuraminidase inhibitor oseltamivir in experimental human inuenza: randomized controlled trials for prevention and treatment. JAMA 282: 1240-1246.
40. Hung IFN, To KKW, Lin CKLCK, Chan JFW, Tse H, et al. (2010) Effect of clinical and virological parameters on the level of neutralizing antibody against pandemic inuenza A virus H1N1 2009. Clin Infect Dis 51: 274-279.
41. Hung IFN, To KKW, Lee CK, Lee KL, Chan K, et al. (2011) Convalescent plasma treatment reduced mortality in patients with severe pandemic inuenza A (H1N1) 2009 virus infection. Clin Infect Dis 52: 447-456.
42. To KKW, Hung IFN, Li IWS, Lee KL, Koo CK, et al. (2010) Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 inuenza virus infection. Clin Infect Dis 50: 850-859.
43. Baz M, Abed Y, McDonald J, Boivin G, (2006) Characterization of multidrug-resistant inuenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis 43: 1555-1561.
44. Gooskens J, Jonges M, Claas ECJ, Meijer A, Kroes ACM, (2009) Prolonged inuenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses. J Infect Dis 199: 1435-1441.
45. Weinstock DM, Gubareva LV, Zuccotti G, (2003) Prolonged shedding of multidrug-resistant inuenza A virus in an immunocompromised patient. New Eng J Med 348: 867.
46. Pinsky BA, Mix S, Rowe J, Ikemoto S, Baron EJ, (2010) Long-term shedding of inuenza A virus in stool of immunocompromised child. Emerg Infect Dis 16: 1165-67.
47. Antón A, López-Iglesias AA, Tórtola T, Ruiz-Camps I, Abrisqueta P, et al. (2010) Selection and viral load kinetics of an oseltamivir-resistant pandemic inuenza A (H1N1) virus in an immuno-compromised patient during treatment with neuraminidase inhibitors. Diag Microbiol Infect Dis 68: 214-219.
48. Boivin G, Goyette N, Bernatchez H, (2002) Prolonged excretion of amantadine-resistant inuenza A virus quasi species after cessation of antiviral therapy in an immunocompromised patient. Clin Infect Dis 34: e23-e25.
49. Campanini G, Piralla A, Rovida F, Puzelli S, Facchini M, et al. (2010) First case in Italy of acquired resistance to oseltamivir in an immunocompromised patient with inuenza A/H1N1v infection. J Clin Virol 48: 220-222.
50. Englund J, Pergam S, Yager J, Mattson D, Whittington N, et al. (2009) Oseltamivir-resistant novel inuenza A (H1N1) virus infection in two immunosuppressed patients seattle, washington, 2009. Morb Mortal Wkly Rep 58: 893-895.
51. Cohen-Daniel L, Zakay-Rones Z, Resnick IB, Shapira MY, Dorozhko M, et al. (2009) Emer-gence of oseltamivir-resistant inuenza A/H3N2 virus with altered hemagglutination pattern in a hematopoietic stem cell transplant recipient. J Clin Vir 44: 138-140.
52. Couturier BA, Bender JM, Schwarz MA, Pavia AT, Hanson KE, et al. (2010) Oseltamivir-resistant inuenza A 2009 H1N1 virus in immunocompromised patients. Inuenza and Other Respiratory Viruses 4: 199-204.
53. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG, (1998) Evidence for zanamivir resistance in an immunocompromised child infected with inuenza B virus. J Infect Dis 178: 1257-1262.
54. Hill-Cawthorne GA, Schelenz S, Laws M, Dervisevic S, (2010) Oseltamivir-resistant pandemic (H1N1) 2009 in patient with impaired immune system. Emerg Infect Dis 16: 1185-1186.
55. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG, (2006) Recovery of drug-resistant inuenza virus from immunocompromised patients: A case series. J Infect Dis 193: 760-764.
56. Klimov AI, Rocha E, Hayden FG, Shult PA, Roumillat LF, et al. (1995) Prolonged shedding of amantadine-resistant inuenza A viruses by immunodeficient patients: Detection by polymerase chain reaction-restriction analysis. J Infect Dis 172: 1352-1355.
57. Mehta T, McGrath E, Bheemreddy S, Salimnia H, Abdel-Haq N, et al. (2010) Detection of oseltamivir resistance during treatment of 2009 H1N1 inuenza virus infection in immunocom-promised patients: Utility of cycle threshold values of qualitative real-time reverse transcriptase PCR. J Clin Microbiol 48: 4326-4328.
58. Renaud C, Boudreault AA, Kuypers J, Lofy KH, Corey L, et al. (2011) H275Y mutant pandemic (H1N1) 2009 virus in immunocompromised patients. Emerg Infect Dis 17: 653-660.
59. van der Vries E, van den Berg B, Schutten M, (2008) Fatal oseltamivir-resistant inuenza viral infection. New Eng J Med 359: 1074.
60. Evans KD, Kline MW, (1995) Prolonged inuenza A infection responsive to rimantadine therapy in a human immunodeficiency virus-infected child. Pediatr Infect Dis J 14: 332-334.
61. Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, et al. (2008) Time lines of infection and disease in human inuenza: A review of volunteer challenge studies. Am J Epidemiol 167: 775-785.
62. Kuiken T, Taubenberger JK, (2008) Pathology of human inuenza revisited. Vaccine 26: D59-D66.
63. Frankova V, Jirasek A, Tumova B, (1977) Type A inuenza: Postmortem virus isolations from different organs in human lethal cases. Arch Virol 53: 265-268.
64. Ghattas C, Mossad S, (2012) Fatal human metapneumovirus and inuenza B virus coinfection in an allogeneic hematopoietic stem cell transplant recipient. Transpl Infect Dis 14: E41-E43.
65. Bal A, Suri V, Mishra B, Bhalla A, Agarwal R, et al. (2012) Pathology and virology findings in cases of fatal inuenza A H1N1 virus infection in 20092010. Histopathology 60: 326-335.
66. Kris R, Yetter R, Cogliano R, Ramphal R, Small P, (1988) Passive serum antibody causes temporary recovery from inuenza virus infection of the nose, trachea and lung of nude mice. Immunol 63: 349-353.
67. Wells MA, Albrecht P, Ennis FA, (1981) Recovery from a viral respiratory infection: 1. inuenza pneumonia in normal and T-deficient mice. J Immunol 126: 1036-1041.
68. García-Sastre A, Durbin RK, Zheng H, Palese P, Gertner R, et al. (1998) The role of interferon in inuenza virus tissue tropism. J Virol 72: 8550-8558.
69. Yap K, Braciale TJ, Ada GL, (1979) Role of T-cell function in recovery from murine inuenza infection. Cell Immunol 43: 341-351.
70. Neff-LaFord HD, Vorderstrasse BA, Lawrence BP, (2003) Fewer CTL, not enhanced NK cells, are sufficient for viral clearance from the lungs of immunocompromised mice. Cellul Immunol 226: 54-64.
71. Lawrence BP, Warren TK, Luong H, (2000) Fewer T lymphocytes and decreased pulmonary inuenza virus burden in mice exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). J Toxicol Environ Health 61: 39-53.
72. Pantelouris EM, Pringle CR, (1976) Interferon production in athymic nude mice. J Gen Virol 32: 149-152.
73. Mbawuike IN, Zhang Y, Couch RB, (2007) Control of mucosal virus infection by inuenza nucleoprotein-specific CD8+ cytotoxic T lymphocytes. Resp Res 8: 44-52.
74. Zweerink H, Skehel SCJ, Crumpton M, Askonas B, (1977) Cytotoxic T cells kill inuenza virus infected cells but do not distinguish between serologically distinct type A viruses. Nature 267: 354-356.
75. Possee R, Schild G, Dimmock N, (1982) Studies on the mechanism of neutralization of inuenza virus by antibody: Evidence that neutralizaing antibody (anti-haemagglutinin) inactivates inuenza virus invivo by inhibiting virion transcriptase activity. J Gen Virol 58: 373-386.
76. Taylor HP, Dimmock NJ, (1985) Mechanisms of neutralization of inuenza virus by IgM. J Gen Virol 66: 903-907.
77. Taylor HP, Dimmock NJ, (1985) Mechanism of neutralization of inuenza virus by secretory IgA is different from that of monomeric IgA or IgG. J Exp Med 161: 198-209.
78. Houglum JE, (1983) Interferon: Mechanisms of action and clinical value. Drug Reviews 2: 20-28.
79. Baglioni C, (1979) Interferon-induced enzymatic activities and their role in the antiviral state. Cell 17: 255-264.
80. Baglioni C, Nilsen T, (1981) The action of interferon at the molecular level. Am Sci 69: 392-399.
81. Epstein LB, Ammann AJ, (1974) Evaluation of T lymphocyte effector function in immunodeficiency diseases: Abnormality in mitogen-stimulated interferon in patients with selective IgA deficiency. J Immunol 112: 617-626.
82. Giovanella BC, Hunter JT, (1984) Use of the nude mouse in immunological research. Methods Enzymol 108: 348-357.
83. Gray PW, Goeddel DV, (1982) Structure of the human immune interferon gene. Nature 298: 859-863.
84. Stark GR, Kerr IM, Williams BRG, Silverman RH, Schreiber RD, (1998) How cells respond to interferons. Ann Rev Biochem 67: 227-264.
85. Merlin G, Falcoff E, Aguet M, (1985) 125I-labelled human interferons alpha, beta and gamma: Comparative receptor-binding data. J Gen Virol 66: 1149-1152.
86. Muller U, Steinhoff U, Reis LL, Hemmi S, Pavlovic J, et al. (1994) Functional-role of type-I and type-II interferons in antiviral defense. Science 264: 1918-1921.
87. Meraz MA, White JM, Sheehan KCF, Bach EA, Rodig SJ, et al. (1996) Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAKSTAT signaling pathway. Cell 84: 431-442.
88. Durbin JE, Hackenmiller R, Simon MC, Levy DE, (1996) Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84: 443-450.
89. García-Sastre A, Egorov A, Matassov D, Brandt S, Levy DE, et al. (1998) Inuenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virol 252: 324-330.
90. Dobrovolny HM, Baron MJ, Gieschke R, Davies BE, Jumbe NL, et al. (2010) Exploring cell tropism as a possible contributor to inuenza infection severity. PLoS ONE 5: e13811.
91. Ferguson NM, Cummings DA, Cauchemez S, Fraser C, Riley S, et al. (2005) Strategies for containing an emerging inuenza pandemic in Southeast Asia. Nature 437: 209-214.
92. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, et al. (1998) Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 282: 103-107.
93. Perelson AS, Neumann A, Markowitz M, Leonard J, Ho D, (1996) HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 271: 1582-1586.
94. Abed Y, Bourgault AM, Fenton RJ, Morley PJ, Gower D, et al. (2002) Characterization of 2 inuenza A(H3N2) clinical isolates with reduced susceptibility to neuraminidase inhibitors due to mutations in the hemagglutinin gene. J Infect Dis 186: 1074-1080.
95. Gubareva LV, Kaiser L, Hayden FG, (2000) Inuenza virus neuraminidase inhibitors. Lancet 355: 827-835.
96. Holford N, Sheiner L, (1981) Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 6: 429-453.
97. Lee N, Chan PKS, Hui DSC, Rainer TH, Wong E, et al. (2009) Viral loads and duration of viral shedding in adult patients hospitalized with inuenza. J Infect Dis 200: 492-500.
98. Narang V, Decraene J, Wong SY, Aiswarya BS, Wasem AR, et al. (2012) Systems immunology: a survey of modeling formalisms, applications and simulation tools. Immunologic Research 53: 251-265.
99. Robinson S, (2008) Conceptual modelling for simulation part I: definition and requirements. J Oper Res Soc 59: 278-290.
100. Craver CF, (2006) When mechanistic models explain. Synthese 153: 355-376.
101. Balci O, (1994) Validation, verification, and testing techniques throughout the life cycle of a simulation study. Ann Oper Res 53: 121-173.
102. Tsang C, (1991) The modeling process and model validation. Ground Water 29: 825-831.
103. Groesser SN, Schwaninger M, (2012) Contributions to model validation: hierarchy, process, and cessation. Sys Dyn Rev 28: 157-181.
104. Callard RE, Turner MW, (1990) Cytokines and Ig switching: Evolutionary divergence between mice and human. Immunol Today 11: 200-203.
105. Farrar JD, Smith JD, Murphy TL, Leung S, Stark GR, et al. (2000) Selective loss of type I interferon-induced STAT4 activation caused by a minisatellite insertion in mouse Stat2. Nature Immunol 1: 65-69.
106. Rogge L, Dambrosio D, Biffi M, Penna G, Minetti LJ, et al. (1998) The role of Stat4 in species- specific regulation of Th cell development by type I IFNs. J of Immunol 161: 6567-6574.
107. Tamura S, Tanimoto T, Kurata T, (2005) Mechanisms of broad cross-protection provided by inuenza virus infection and their application to vaccines. Jpn J Infect Dis 58: 195-207.
108. Narasaraju T, Sim M, Ng H, Phoon M, Shanker N, et al. (2009) Adaptation of human inuenza H3N2 virus in a mouse pneumonitis model: insights into viral virulence, tissue tropism and host pathogenesis. Microb Infect 11: 2-11.
109. Wu R, Zhang H, Yang K, Liang W, Xiong Z, et al. (2009) Multiple amino acid substitutions are involved in the adaptation of H9N2 avian inuenza virus to mice. Vet Microbiol 138: 85-91.
110. Koerner I, Matrosovich MN, Haller O, Staeheli P, Kochs G, (2012) Altered receptor specificity and fusion activity of the haemagglutinin contribute to high virulence of a mouse-adapted inuenza A virus. J Gen Virol 93: 970-979.
111. Mitchell H, Levin D, Forrest S, Beauchemin CA, Tipper J, et al. (2011) Higher level of replication efficiency of 2009 (H1N1) pandemic inuenza virus than those of seasonal and avian strains: Kinetics from epithelial cell culture and computational modeling. J Virol 85: 1125-1135.
112. Canini L, Carrat F, (2011) Population modeling of inuenza A/H1N1 virus kinetics and symptom dynamics. J Virol 85: 27642770.
113. Lee N, Chan PKS, Wong CK, Wong KT, Choi KW, et al. (2011) Viral clearance and inammatory response patterns in adults hospitalized for pandemic 2009 inuenza A(H1N1) virus pneumonia. Antivir Ther 16: 237-247.
114. Waldman RH, Mann JJ, Kasel JA (1968) Inuenza virus neutralizing antibody in human respiratory secretions. J Immunol 100.
115. Zahradnik JM, Kasel JA, Martin RR, Six HR, Cate TR, (1983) Immune responses in serum and respiratory secretions following vaccination with a live cold-recombinant (CR35) and inactivated A/USSR/77 (H1N1) inuenza virus vaccine. J Med Virol 11: 277-285.
116. Mitchell M Engauge Digitizer A free open-source software to extract data points from a graph image. Hosted on SourceForge at http://digitizer.sourceforge.net.
117. Eaton JW, et al. (2008) GNU Octave version 3.0.5. A free open-source software for solving linear and nonlinear problems numerically, and for performing other numerical experiments using a language that is mostly compatible with Matlab. Available at: http://www.octave.org/.
118. Yap K, Ada G, (1978) Cytotoxic T cells in the lungs of mice infected with an inuenza A virus. Scand J Immunol 7: 73-80.